Development of peptidic MERS-CoV entry inhibitors.
- Author:
Shuai XIA
;
Qian WANG
;
Shu-wen LIU
;
Lu LU
;
Shi-bo JIANG
- Publication Type:Journal Article
- MeSH:
Antiviral Agents;
pharmacology;
Coronavirus Infections;
drug therapy;
Dipeptidyl Peptidase 4;
metabolism;
Drug Design;
Humans;
Middle East Respiratory Syndrome Coronavirus;
drug effects;
physiology;
Peptides;
pharmacology;
Spike Glycoprotein, Coronavirus;
metabolism;
Virus Internalization;
drug effects
- From:
Acta Pharmaceutica Sinica
2015;50(12):1513-1519
- CountryChina
- Language:Chinese
-
Abstract:
In 2012, a new SARS-like coronavirus emerged in the Middle East, namely the Middle East respiratory syndrome coronavirus (MERS-CoV). It has caused outbreaks with high mortality. During infection of target cell, MERS-CoV S protein S1 subunit binds to the cellular receptor (DPP4), and its S2 subunit HR1 and HR2 regions intact with each other to form a stable six-helix bundle to mediate the fusion between virus and target cell membranes. Hence, blocking the process of six-helix bundle formation can effectively inhibit MERS-CoV entry into the target cells. This review focuses on the recent advance in the development of peptidic entry inhibitors targeting the MERS-CoV S2 subunit.
